Intuitive Surgical

Stryker has agreed to invest roughly $400m in UK-based CMR Surgical and secured exclusive US sales rights for its Versius surgical robot, strengthening its challenge to Intuitive Surgical's dominant da Vinci system. Versius' modular design, using separate robotic arm carts that teams can arrange around the operating table, is seen as a key differentiator as the two companies compete in soft-tissue robotic surgery.

Intuitive Surgical, the maker of the da Vinci surgical robot traded on Nasdaq under the ticker ISRG, is being closely watched by investors seeking its latest stock price, quotes and company news. The medical device maker is a frequent focus for those tracking healthcare and robotics stocks, and market watchers are checking its current valuation and recent developments.

Medical device maker Stryker has announced a $400 million investment in CMR Surgical, marking its entry into the soft tissue robotics market. The move puts Stryker in competition with established players like Intuitive Surgical in the fast-growing surgical robotics sector, and signals the company's ambition to expand beyond its orthopedic robotics business.

Johnson & Johnson is offering a look at the development of its OTTAVA robotic surgical system, the company's general surgery robot designed to compete in the fast-growing surgical robotics market dominated by Intuitive Surgical's da Vinci platform. The company is highlighting the engineering work behind the system as it moves through development toward clinical use.

Medical device maker Stryker has agreed to pay $400 million for CMR Surgical's Versius soft-tissue robotic surgery system, moving the company deeper into surgical robotics. The deal hands Stryker a flexible robotic platform used in minimally invasive procedures, and industry watchers see it as a challenge to Intuitive Surgical's dominance in soft-tissue robotics and part of a broader consolidation wave among surgical robotics makers.